QIAGEN

Tiny grant application, huge rewards! In only 200 words or fewer, your lab could be among the first to get their hands on QIAmini. Apply now ➡️ https://lnkd.in/eccE42Hz. You got this. What does QIAmini do? It purifies DNA and RNA while you keep your science moving. For up to 8 samples at a time: Prepare, load, and press a button. It’s also small, fitting on a sheet of printer paper. Put it anywhere. And it uses magnetic bead technology for purification. So, consistency and reliability go without saying. Applications are open to anyone performing life sciences research at an institution (e.g., technician, student, post-doc, scientist, principal investigator, etc…) or anyone accepted for a Master’s, MD and PhD program. A total of five grants will be awarded. The awardee’s institution will receive: ✅One QIAmini ✅Two of the following QIAmini kits of your choice: QIAmini RNA Tissue/Cells Kit, QIAmini DNA Tissue/Cells Kit, QIAmini DNA Blood Kit, QIAmini Pathogen Kit, QIAmini PowerFecal Pro DNA/RNA Kit 200 words? That’s nothing, only about the length of this post.

Patients with rheumatic diseases face unique TB screening challenges. Evidence from three new studies shows that QFT-Plus helps reliably identify TB infection among immunocompromised individuals, supporting risk-based screening decisions across care settings. Learn more ➡️https://lnkd.in/eJzvdm66 Across both endemic and low-prevalence settings, these studies highlight the importance of routine screening for TB infection in patients receiving or preparing to receive immunosuppressive therapies. Researchers found that QFT-Plus identified infections that would have been missed using patient history and chest X-ray alone. QFT-Plus can also help clinicians focus follow-up testing where it is most relevant, supporting efficient long-term management of patients receiving DMARD therapy. These studies reinforce confidence for healthcare providers already using QuantiFERON-TB Gold Plus and highlight the importance of modern TB infection screening for programs that still rely on skin testing or do not routinely screen at-risk rheumatology patients. #Tuberculosis #Rheumatology #LatentTB #TBScreening #QFTPlus

Every patient deserves answers. Behind each one is a lab team whose work helps shape clinical care decisions. We’re heading to ADLM 2026 to connect with the people who make diagnostic medicine happen every day. We’re looking forward to conversations about the challenges labs are navigating – from urgent, overlapping symptoms to silent risks – and how automation can support the work behind confident clinical decisions. At booth 1077, our team will be highlighting developments across syndromic testing, automated tuberculosis infection testing and clinical sample extraction. Heading to ADLM? Make us one of your stops. #ADLM2026 #LaboratoryMedicine #MolecularDiagnostics

New methodologies can create powerful opportunities for discovery, especially with the right guidance to help you get started with confidence. In our latest newsletter, we highlight a webinar series that breaks down single-cell RNA sequencing into four practical sessions covering the key stages of the workflow. Whether you’re new to scRNA-seq and exploring its possibilities, or looking to strengthen your approach, read on to find the right session to jump into.

Pancreatic cancer is one of the deadliest cancers, largely because it is so rarely caught early. In Brazil, one researcher is working to change that with a simple blood test. Read his story 👉 https://lnkd.in/dAqdv-CS Its early symptoms are easy to miss: back pain, fatigue, unexplained weight loss, all mild and often mistaken for far more common conditions. At the Oswaldo Cruz Foundation's Instituto Carlos Chagas in Curitiba, molecular biologist Mateus Nóbrega Aoki is investigating whether liquid biopsy, a blood test that reads tumor signals in cell-free DNA, could enable earlier detection and one day support a nationwide screening strategy. "We are using very sensitive and specific methodologies, such as next generation sequencing and digital PCR, to look for specific biomarkers for pancreatic cancer detection," Aoki explains. His team runs an end-to-end workflow on our technologies: stabilizing fragile cell-free DNA at collection, isolating and sequencing it, interpreting the variants and precisely quantifying them with QIAcuity Digital PCR. Sample to Insight, applied to one of the toughest cancers to catch in time. Catching pancreatic cancer sooner could give patients something they rarely get today: time. Helping researchers like Mateus win that time is exactly what we're building for.

A few months ago, two interns joined our project management team in Manchester for 12 weeks each. By the end, their manager recommended we do it all again.   Lois Gardner from The University of Manchester and Paula Wasiolek BSc MSc (ANutr) from Manchester University NHS Foundation Trust were in the thick of real work the whole time, supporting team meetings, planning project timelines and building the documentation the team relies on. They also worked across different kinds of projects, which gave them a feel for how managing external projects differs from internal ones.   It clearly landed. Lois said the placement "provided meaningful insight into the highly regulated biotechnology sector," and helping someone understand our world that quickly is exactly what we hoped for.   Their manager, Mike Evershed, MAPM, summed it up: "Both integrated themselves fully into the Project Management Team, and I was very impressed with both their attitude and the quality of what they produced during their short time with us. Having their support on the projects was exceptionally useful, and I would definitely recommend that we go through the process again."   This was part of our partnership with the NIHR Biomedical Research Centre: Manchester, and that recommendation is exactly where our heads are. We're already thinking about what next year's placements could look like.   Lois and Paula, thank you. You raised the bar.

Every hour matters when treating bloodstream infections. That's why we've expanded the QIAstat-Dx bloodstream infection testing menu in Europe with the new CE-IVDR-certified QIAstat-Dx BCID GN Plus AMR Panel. Learn more 👉 https://lnkd.in/dVZ37Rqz   The launch builds on the recently introduced QIAstat-Dx BCID GPF Plus AMR Panel, creating a comprehensive bloodstream infection testing offering on the QIAstat-Dx platform.   Together, the two panels detect 33 pathogen targets and 28 antimicrobial resistance markers, helping laboratories identify clinically relevant pathogens and resistance mechanisms in about one hour to support earlier pathogen identification, faster treatment decisions, antimicrobial stewardship and infection control.   By continuing to expand the QIAstat-Dx syndromic testing menu, we’re helping laboratories deliver timely, actionable insights across a growing range of infectious disease applications.

Olga left Ukraine the morning the war began, with little more than a backpack. She had to start her life over from scratch. What she found at QIAGEN was a job, and something she never expected. She was searching for work far from home while holding her family together, her young son and her parents. Providing for them was everything. A single LinkedIn post led her to QIAGEN. People in her network shared it, someone encouraged her to apply, and from application to offer took just 19 days. But what stayed with her wasn't the speed. It was the people. "It was not only about the job. People were ready to open their hearts and their homes, to give us a chance to start. I say this on behalf of all Ukrainians." Colleagues at QIAGEN helped 🇺🇦 Olga Vedernikova and her parents find a place to stay while they found their feet. That welcome is part of who we are at QIAGEN. Fifteen years of marketing across healthcare and consumer brands had carried Olga this far. Today she is a Global Campaign Manager at QIAGEN, working with teams across regions, and several colleagues have become friends. She still carries home with her. "I miss my home. But this has become my second home." Behind every colleague is a human story. Olga's is one of resilience, and of a team that opened a door when it mattered most. Follow QIAGEN for more stories from the people behind our work.

A clinician racing to confirm sepsis. A food scientist hunting a pathogen in a sample of poultry. A water utility watching for the next public health threat. Three very different people, asking three very different questions, and one technology quietly answering all of them: digital PCR. Our latest QIAGEN Deep Dive goes inside QIAcuity, our digital PCR solution, and the places it is making a difference. Watch it on-demand 👉 https://lnkd.in/dJfmRy63 Inside, you will see how far it reaches: confirming sepsis in about five hours at Brown University Health, catching a cancer's return at Tracer Bio, quantifying cell and gene therapies at Novartis and Cellares, protecting the food supply at Florida State University and reading a city's health in its wastewater at Berliner Wasserbetriebe. Different fields, different stakes, one need underneath: knowing exactly what is in a sample and how much of it. That is the through-line of the whole Deep Dive. Not a single breakthrough, but a technology that keeps earning its place wherever a precise, trustworthy answer matters. That is what we built QIAcuity to deliver.

Your genome is nearly identical to everyone else's. Your gut microbiome is not. It is shaped by what you eat, where you live and the culture you grew up in.   That difference hides a real problem. Most of what science knows about the microbiome comes from populations that look nothing like Southeast Asia, so precision medicine built on that data does not truly fit the people of the region.   In Singapore, AMILI is setting out to change that. As Southeast Asia's leading precision gut microbiome company, the team is building Southeast Asia's largest multiethnic gut microbiome database, with one goal: ground precision medicine in Asian data instead of global norms. Their work runs from microbiome profiling and clinical research to fecal microbiota transplantation for microbiome-linked diseases.   Turning thousands of stool samples into reliable data is no small task. Behind the science, the team relies on automated nucleic acid isolation with QIAGEN's EZ2 PowerFecal Pro DNA/RNA Kit on the EZ2 Connect.   What does it take to build a microbiome map that finally reflects a whole region? Full story in the comments 👇